The University of Michigan, in partnership with pharmaceutical company AstraZeneca, is recruiting participants for phase 3 of a COVID-19 vaccine clinical trial.
The study is evaluating the vaccine AZD1222.
Hundreds of patients are needed to immediately participate in the trial. And across several states, AstraZeneca has a goal of including 30,000 individuals in the trial over a period of two years.
“The importance of a safe and effective vaccine against COVID-19 cannot be overstated," said Marschall Runge, M.D., Ph.D., Dean, U-M Medical School. "The AstraZeneca Phase III trial will bring answers as to the effectiveness of this vaccine. At the end of the day, this kind of rigorous clinical trial with the commitment of Michigan Medicine and other study sites to safety will be a key step in realizing a vaccine that will save lives when one is developed."
To take part in the trial, you must be 18 or older, in good or stable health (you may have an underlying medical condition and still take part, if your disease is stable), and you must not have had a previously confirmed diagnosis of COVID-19.
To sign up to volunteer, click here.
Additional Coronavirus information and resources:
Click here for a page with resources including a COVID-19 overview from the CDC, details on cases in Michigan, a timeline of Governor Gretchen Whitmer's orders since the outbreak, coronavirus' impact on Southeast Michigan, and links to more information from the Michigan Department of Health and Human Services, the CDC and the WHO.
View a global coronavirus tracker with data from Johns Hopkins University.
See complete coverage on our Coronavirus Continuing Coverage page.
Visit our The Rebound Detroit, a place where we are working to help people impacted financially from the coronavirus. We have all the information on everything available to help you through this crisis and how to access it.